Medicine and Dentistry
Age
5%
Analysis
6%
Bevacizumab
8%
BRCA Mutation
7%
BRCA1
22%
BRCA2
6%
Breast Cancer
10%
Cancer
6%
Cancer Therapy
5%
Carboplatin
5%
Cervical Cancer
11%
Chemotherapy
23%
Combination Therapy
18%
Complication
8%
Cytoreductive Surgery
20%
Diagnosis
9%
Diseases
19%
Endometrial Cancer
12%
Female Genital Tract Cancer
5%
Follow up
9%
Inpatient
16%
Krukenberg Tumor
7%
Malignant Neoplasm
9%
Meta-Analysis
7%
Metastatic Carcinoma
5%
Neoadjuvant Chemotherapy
12%
Neoplasm
15%
Olaparib
10%
Ovarian Cancer
65%
Ovary
6%
Overall Survival
8%
Paclitaxel
5%
PARP Inhibitor
10%
Patient
100%
Pelvis
5%
Platinum
14%
Progression Free Survival
12%
Radiation Therapy
5%
Recurrent Disease
21%
Recurrent Ovarian Cancer
13%
Relapse
5%
Retroperitoneal Lymph Node Dissection
6%
Salpingooophorectomy
9%
Surgery
29%
Survival
14%
Therapeutic Procedure
50%
Toxicity
6%
Vulvar Cancer
5%
Woman
26%
Pharmacology, Toxicology and Pharmaceutical Science
Bevacizumab
5%
Chemotherapy
23%
Clinical Trial
6%
Diseases
7%
Olaparib
6%
Ovary Cancer
29%
Overall Survival
5%
Paclitaxel
7%
Platinum
9%
Progression Free Survival
7%
Recurrent Disease
5%
Toxicity
10%
Uterine Cervix Cancer
7%
